Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173976 · ClinicalTrials.gov registry record · Phase 1
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
A Phase 1 study of Chondrosarcoma, sponsored by Mohammed Milhem.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03173976 is a Phase 1 study of Chondrosarcoma that is active but no longer recruiting, run by Mohammed Milhem. The registered enrollment target is 17 participants, below the 127-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03173976, a Phase 1 study of Chondrosarcoma, is active but no longer recruiting, sponsored by Mohammed Milhem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03173976
The ClinicalTrials.gov registry entry for NCT03173976 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (87% lower). The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chondrosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT03173976 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03173976 about?
NCT03173976 is a clinical study titled "Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial". The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
What is the current status of trial NCT03173976?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-07-18. Estimated completion is 2028-05-01.
What conditions does trial NCT03173976 study?
This clinical trial studies the following conditions: Chondrosarcoma.
What interventions are being tested in trial NCT03173976?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT03173976?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03173976 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RECRUITING
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.